首页> 外文OA文献 >PD10-09 THE PROSPER TRIAL: CHEMOTHERAPY-RELATED ENDPOINTS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH ENZALUTAMIDE

【2h】

PD10-09 THE PROSPER TRIAL: CHEMOTHERAPY-RELATED ENDPOINTS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH ENZALUTAMIDE

机译：PD10-09繁荣试验：用烯甲酰胺处理的非容性阉割前列腺癌患者的化疗相关终点

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Neal Shore; Fred Saad; Maha Hussain; Karim Fizazi; Per Rathenborg; Eren Demirhan; Katharina Modelska; De Phung; Andrew Krivoshik; Cora N. Sternberg;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial [J] . Tombal Bertrand, Saad Fred, Penson David, The lancet oncology . 2019,第4期

机译：患有非转移性，抗阉割前列腺癌（Prosper）（Prosper）的男性后苯甲酰胺酰胺或安慰剂的患者报告的结果：多期，随机，双盲，第3期试验
2. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial [J] . SternbergC.N., deBonoJ.S., ChiK.N., Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第2期

机译：雄激素受体抑制剂恩杂鲁胺治疗的老年转移性去势抵抗性前列腺癌患者的预后得到改善：AFFIRM III期试验的结果
3. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial [J] . SternbergC.N., deBonoJ.S., ChiK.N., Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第2期

机译：通过雄激素受体抑制剂烯醇酰胺处理的老年转移性阉割前列腺癌的老年患者的改善结果：III期肯定试验的结果
4. Castration-Resistant Prostate Cancer: Novel Targets, Agents, and Trials [C] . Evan Y. Yu Genitourinary Cancers Symposium . 2012

机译：抗阉割前列腺癌：新型靶点，药剂和试验
5. The Role of SOX2 in Regulating Metabolism and Enzalutamide Resistance in Prostate Cancer [D] . de Wet, Larischa . 2020

机译：SOX2在治疗前列腺癌中调节代谢和依齐甲酰胺抗性的作用
6. Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine Nilutamide and Combination Therapy: Implications for Vaccine Clinical Trial Design [O] . Ravi A. Madan, James L. Gulley, Jeffrey Schlom, -1

机译：疫苗尼鲁胺和联合疗法治疗的非转移性去势抵抗性前列腺癌患者的总生存期分析：疫苗临床试验设计的意义
7. MP34-17 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POST HOC ANALYSIS OF PROSPER BY PROSTATE SPECIFIC-ANTIGEN PROGRESSION [O] . Fred Saad*, Cora N. Sternberg, Eleni Efstathiou, 2019

机译：MP34-17患有非容性阉割前列腺癌患者烯醇酰胺的34-17阶段3，随机，双盲，安慰剂对照研究：前列腺特异性抗原进展繁殖后的HOC分析

PD10-09 THE PROSPER TRIAL: CHEMOTHERAPY-RELATED ENDPOINTS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH ENZALUTAMIDE

著录项

引文网络

相似文献

相关主题

期刊订阅